The COAST-V trial (NCT02696785) investigated the efficacy and safety of ixekizumab in patients with radiographic axial spondyloarthritis who were biological disease-modifying anti-rheumatic drug naïve. It was a pleasure to talk with Dr. Sofia Ramiro (Leiden University Medical Center, Leiden, Netherlands) to discuss the findings in terms of patient reported outcomes at weeks 16 and 52 in the study.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Efficacy and Improvement in Patient-Reported Outcomes at Weeks 16 and 52 in Ixekizumab Treated Biological Naïve Patients with Radiographic Axial Spondyloarthritis Achieving Clinically Important Pain at Night Reduction at Week 16: Results from COAST-V Trial.’ (Abstract number: 1009) was presented at the ACR Convergence, November 10–14, 2022.
Disclosures: Sofia Ramiro discloses receiving grant/ research support from AbbVie, Galapagos, Novartis, Pfizer, and UCB; and honoraria from AbbVie, Eli Lilly, MSD, Novartis, Pfizer, UCB, and Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
Poster reprinted from ACR Convergence held November 10–14, 2022. The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by Touch Medical Media Ltd.
